CombiMatrix, Manhattan Labs Announce Strategic Partnership

CombiMatrix Corporation

and Manhattan Labs jointly announced today that they have entered into a strategic partnership under which Manhattan Labs will market and distribute CombiMatrix microarray tests for the miscarriage management testing market in the New York City metropolitan area. The partnership was enabled by the announcement in late June that CombiMatrix miscarriage management tests had received conditional approval from the New York State Department of Health for testing on patient samples within the state. Manhattan Labs is a high-end, independent clinical laboratory that serves the New York City metropolitan area. Women's health, particularly obstetrics and reproductive issues, is one of Manhattan Lab's specialties, noted Chief Executive Officer Ken Cerney. "Our goal is to be the premier, full-service independent clinical laboratory in the New York City area," Cerney said. "Our labs offer the highest quality testing for all patients and now we have added a new focus on miscarriage management. We believe adding the operational and analytical support of CombiMatrix will be beneficial to our physician customers and their patients, and will expand the